University of Iowa Hosptials and Clinics
Welcome,         Profile    Billing    Logout  
 8 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zakharia, Yousef
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hourglass May 2024 - Dec 2024 : Completion of enrollment in P2 portion for mCRPC
Recruiting
2/3
60
US
FPI-2265, Ac225-PSMA I&T
Fusion Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
07/26
01/31
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Recruiting
2
140
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
10/25
09/26
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
NKT2152-101, NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
1/2
128
US
Oral NKT2152
NiKang Therapeutics, Inc.
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
05/25
09/26
NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting
1/2
264
US
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Perspective Therapeutics
Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
12/27
12/29
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT03957551: Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Active, not recruiting
1/2
28
US
Cabozantinib, XL184, COMETRIQ™, Cabometyx®, Pembrolizumab, Keytruda
John Rieth, Exelixis, University of Iowa
Advanced Metastatic Melanoma
06/24
12/26
AVETAX, NCT03575013: A Combination of Avelumab and Taxane () for Urothelial Cancer

Active, not recruiting
1
21
US
Avelumab, MSB0010718C, Docetaxel, Taxotere
Yousef Zakharia, Pfizer, University of Iowa
Urothelial Carcinoma
12/21
02/26
NCT02535533: SLM + Axitinib for Clear Cell RCC

Active, not recruiting
1
46
US
Selenomethionine (SLM), Axitinib
Bilal G. Rahim, Pfizer
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
08/23
05/26
NCT03324373: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Active, not recruiting
1
11
US
Lenvatinib, LENVIMA®, KISPLYX®, Everolimus, AFINITOR®, Partial or Radical Cytoreductive Nephrectomy
Yousef Zakharia, Eisai Inc.
Renal Cell Carcinoma
09/23
06/28
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
Anderson, Marian
BTCRC-HN17-111, NCT03942653: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Recruiting
2
20
US
Goserelin Acetate, Pembrolizumab
Manish Patel, Merck Sharp & Dohme LLC
Salivary Gland Carcinoma
09/25
10/25
BTCRC-HEM15-027, NCT03681561: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
1/2
54
US
Ruxolitinib, Jakafi, Nivolumab, Opdivo
Veronika Bachanova, Incyte Corporation, Bristol-Myers Squibb
Hodgkin Lymphoma
07/25
07/27

Download Options